[go: up one dir, main page]

FI3525583T3 - Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä - Google Patents

Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä

Info

Publication number
FI3525583T3
FI3525583T3 FIEP17859451.1T FI17859451T FI3525583T3 FI 3525583 T3 FI3525583 T3 FI 3525583T3 FI 17859451 T FI17859451 T FI 17859451T FI 3525583 T3 FI3525583 T3 FI 3525583T3
Authority
FI
Finland
Prior art keywords
region comprises
sequence
seq
seo
region
Prior art date
Application number
FIEP17859451.1T
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Nancy Stagliano
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Application granted granted Critical
Publication of FI3525583T3 publication Critical patent/FI3525583T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

Patenttivaatimukset
1. Vasta-aine, joka käsittää raskasketjun ja kevytketjun, jossa raskasketju käsittää raskasketjun vaihtelevan (VH) alueen ja raskasketjun vakioalueen, ja kevytketju käsittää kevytketjun vaihtelevan (VL) alueen; jossa VL-alue käsittää VL:n komplementaarisuuden määrittävän alueen (CDR) 1, VL:n CDR2:n ja VL:n CDR3:n, ja jossa VH-alue käsittää VH:n CDR1:n, VH:n CDR2:n ja VH:n CDR3:n; jossa VL:n CDR1 käsittää sekvenssin SEQ ID NO: 1; jossa VL:n CDR2 käsittää sekvenssin SEO ID NO: 2; jossa VL:n CDR3 käsittää sekvenssin SEQ ID NO: 3; jossa VH:n CDR1 käsittää sekvenssin SEQ ID NO: 4; jossa VH:n CDR2 käsittää sekvenssin SEO ID NO: 5; jossa VH:n CDR3 käsittää sekvenssin SEO ID NO: 6; jossa raskasketjun vakioalue käsittää sekvenssin, joka on vähintään 95-prosenttisesti identtinen sekvenssin SEO ID NO: 28 kanssa, jossa sekvenssiä SEO ID NO: 28 vastaava raskasketjun vakioalueen aminohappotähde 308 on Leu, ja sekvenssiä SEQ ID NO: 28 vastaava raskasketjun vakioalueen aminohappotähde 314 on Ser; jossa vasta-aine sitoo spesifisesti aktivoitunutta Cls:ää ja jossa sillä on pidempi puoliintumisaika verrattuna vertailukelpoisiin anti-Cls-vasta-aineisiin, joilla on villityypin Fc-alue, joka on sekvenssin SEO ID NO: 52 mukainen, tai Fc-alue, joka on sekvenssin SEO ID NO: 53 mukainen.
2. Patenttivaatimuksen 1 mukainen vasta-aine, jossa sekvenssiä SEQ ID NO: 28 vastaava raskasketjun vakioalueen aminohappotähde 108 on Pro ja/tai jossa sekvenssiä SEO ID NO: 28 vastaava fraskasketjun vakioalueen aminohappotähde 115 on Glu.
3. Patenttivaatimuksen 1 tai 2 mukainen vasta-aine, jossa raskasketjun vakioalue käsittää sekvenssin SEO ID NO: 28.
4. Jonkin patenttivaatimuksista 1-3 mukainen vasta-aine, jossa VL-alue käsittää aminohapposekvenssin valittuna ryhmästä, joka koostuu sekvensseistä SEO ID NO: 20, 22 ja 24 ja/tai jossa VH-alue käsittää aminohapposekvenssin valittuna ryhmästä, joka koostuu sekvensseistä SEO ID NO: 10, 12, 14, 16 ja 18.
5. Jonkin patenttivaatimuksista 1-4 mukainen vasta-aine, jossa: (a) VH-alue käsittää sekvenssin SEQ ID NO:10 ja VL-alue käsittää sekvenssin SEO ID NO:20; (b) VH-alue käsittää sekvenssin SEQ ID NO:10 ja VL-alue käsittää sekvenssin SEO ID NO:22; (c) VH-alue käsittää sekvenssin SEQ ID NO:10 ja VL-alue käsittää sekvenssin SEO ID NO:24; (d) VH-alue käsittää sekvenssin SEQ ID NO:1? ja VL-alue käsittää sekvenssin SEO ID NO:20; (e) VH-alue käsittää sekvenssin SEO ID NO:12 ja VL-alue käsittää sekvenssin SEO ID NO:22; (f) VH-alue käsittää sekvenssin SEO ID NO:12 ja VL-alue käsittää sekvenssin SEO ID NO:24; (g) VH-alue käsittää sekvenssin SEO ID NO:14 ja VL-alue käsittää sekvenssin SEO ID NO:20; (h) VH-alue käsittää sekvenssin SEO ID NO:14 ja VL-alue käsittää sekvenssin SEO ID NO:22;
(i) VH-alue käsittää sekvenssin SEO ID NO:14 ja VL-alue käsittää sekvenssin SEO ID NO:24; (J) VH-alue käsittää sekvenssin SEO ID NO:16 ja VL-alue käsittää sekvenssin SEO ID NO:20; (J) VH-alue käsittää sekvenssin SEQ ID NO:16 ja VL-alue käsittää sekvenssin SEO ID NO:22; (k) VH-alue käsittää sekvenssin SEO ID NO:16 ja VL-alue käsittää sekvenssin SEO ID NO:24; (1) VH-alue käsittää sekvenssin SEO ID NO:18 ja VL-alue käsittää sekvenssin SEO ID NO:20; (m) VH-alue käsittää sekvenssin SEO ID NO:18 ja VL-alue käsittää sekvenssin SEQ ID NO:22; tai (n) VH-alue käsittää sekvenssin SEO ID NO:18 ja VL-alue käsittää sekvenssin SEO ID NO:24.
6. Jonkin patenttivaatimuksista 1-5 mukainen vasta-aine, jossa VH-alue käsittää sekvenssin SEO ID NO:14 ja VL- alue käsittää sekvenssin SEQ ID NO:22.
7. Jonkin patenttivaatimuksista 1-6 mukainen vasta-aine, jossa kevytketju käsittää lisäksi kevytketjun vakioalueen, jossa edullisesti kevytketjun vakioalue käsittää sekvenssin SEO ID NO: 45.
8. Jonkin patenttivaatimuksista 1-7 mukainen vasta-aine, jossa raskasketju käsittää sekvenssin SEO ID NO: 29 ja/tai jossa kevytketju käsittää sekvenssin SEO ID NO:
30.
9. Jonkin patenttivaatimuksista 1-8 mukainen vasta-aine, joka on hbispesifinen vasta-aine tai multispesifinen vasta-aine.
10. Immunokonjugaatti, joka käsittää jonkin patenttivaatimuksista 1-9 mukaisen vasta-aineen.
11. Nukleiinihappo tai nukleiinihappojen joukko, joka koodaa jonkin patenttivaatimuksista 1-9 mukaista vasta- ainetta.
12. Vektori tai vektorien joukko, joka käsittää patenttivaatimuksen 11 mukaisen nukleiinihapon tai nukleiinihappojen joukon.
13. Isäntäsolu, joka käsittää patenttivaatimuksen 11 mukaisen nukleiinihapon tai nukleiinihappojen joukon tai patenttivaatimuksen 12 mukaisen vektorin tai vektorien joukon.
14. Farmaseuttinen koostumus, joka käsittää jonkin patenttivaatimuksista 1-9 mukaisen vasta-aineen, patenttivaatimuksen 10 mukaisen immunokonjugaatin, patenttivaatimuksen 11 mukaisen nukleiinihapon tai nukleiinihappojen joukon, patenttivaatimuksen 12 mukaisen vektorin tai vektorien joukon tai patenttivaatimuksen 13 mukaisen isäntäsolun ja farmaseuttisesti hyväksyttävän apuaineen.
15. Jonkin patenttivaatimuksista 1-9 mukainen vasta- aine, patenttivaatimuksen 10 mukainen immunokonjugaatti, patenttivaatimuksen 11 mukainen nukleiinihappo tai nukleiinihappojen joukko, patenttivaatimuksen 12 mukainen vektori tai vektorien joukko, patenttivaatimuksen 13 mukainen isäntäsolu tai patenttivaatimuksen 14 mukainen farmaseuttinen koostumus käytettäväksi komplementtivälitteisen sairauden tai häiriön hoidossa tai komplementtireitin estämiseksi sitä tarvitsevassa kohteessa.
FIEP17859451.1T 2016-10-12 2017-10-12 Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä FI3525583T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3525583T3 true FI3525583T3 (fi) 2025-10-31

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17859451.1T FI3525583T3 (fi) 2016-10-12 2017-10-12 Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä

Country Status (30)

Country Link
US (2) US20200048332A1 (fi)
EP (2) EP4652926A2 (fi)
JP (3) JP7069138B2 (fi)
KR (1) KR102638884B1 (fi)
CN (2) CN116554320A (fi)
AR (1) AR110677A1 (fi)
AU (3) AU2017341766A1 (fi)
BR (1) BR112019007309A2 (fi)
CA (1) CA3040253A1 (fi)
CL (1) CL2019000975A1 (fi)
CO (1) CO2019004741A2 (fi)
CR (1) CR20190223A (fi)
DK (1) DK3525583T3 (fi)
DO (1) DOP2019000085A (fi)
EA (1) EA201990884A1 (fi)
EC (1) ECSP19033211A (fi)
FI (1) FI3525583T3 (fi)
HR (1) HRP20251304T1 (fi)
IL (2) IL265957B2 (fi)
LT (1) LT3525583T (fi)
MX (2) MX2019004259A (fi)
MY (1) MY198182A (fi)
PE (1) PE20191031A1 (fi)
PH (1) PH12019500789A1 (fi)
PT (1) PT3525583T (fi)
SG (1) SG11201903012RA (fi)
TN (1) TN2019000109A1 (fi)
TW (3) TW202434298A (fi)
WO (1) WO2018071676A1 (fi)
ZA (1) ZA201902247B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
AU2016246452B2 (en) 2015-04-06 2022-03-10 Bioverativ Usa Inc. Humanized anti-C1s antibodies and methods of use thereof
LT3525583T (lt) 2016-10-12 2025-11-10 Anti-c1s antikūnai ir jų naudojimo būdai
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
US11242382B2 (en) * 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies
CN115427445A (zh) * 2020-04-22 2022-12-02 彻莫马布有限公司 使用抗ccl24抗体的治疗方法
JP2023527684A (ja) * 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド 神経疾患を治療するための補体成分ｃ１ｓ阻害剤、並びにそれを使用する関連組成物、システム及び方法
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
JP2024518844A (ja) 2021-05-20 2024-05-07 ダイアンサス セラピューティクス オプコ， インコーポレイテッド Ｃ１ｓに結合する抗体およびその使用
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
CN119730882A (zh) 2022-06-24 2025-03-28 美国比奥维拉迪维股份有限公司 用于治疗补体介导的疾病的方法
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
US20240401082A1 (en) 2023-03-16 2024-12-05 Genzyme Corporation Treatment of Dry Age-Related Macular Degeneration

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1276103C (en) 1984-10-02 1990-11-13 Fumiaki Taguchi Substance-conjugated complement component c1q
JPS61271455A (ja) 1985-05-28 1986-12-01 Olympus Optical Co Ltd 免疫学的分析方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
DK0716611T3 (da) 1993-09-01 2002-05-21 Sanquin Bloedvoorziening Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
WO1996017951A2 (en) 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
ES2153654T3 (es) 1996-10-17 2001-03-01 Oxford Biomedica Ltd Vectores retrovirales.
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP2277920B1 (en) 1998-02-20 2014-06-11 Genentech, Inc. Inhibitors of complement activation
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
JP2003529536A (ja) 1999-02-09 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物
AU4369000A (en) 1999-04-26 2000-11-10 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2001053825A1 (en) 2000-01-19 2001-07-26 Biotransplant, Inc. Swine defective for transmission of porcine endogenous retrovirus and uses thereof
DE60132169T2 (de) 2000-01-31 2008-12-11 Pharming Intellectual Property Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
ATE435873T1 (de) 2000-03-23 2009-07-15 Genentech Inc Anti-c2/c2a inhibitoren zur komplement aktivierung
AU2001282857A1 (en) 2000-06-21 2002-01-02 Zymogenetics Inc. Peptide and polypeptide inhibitors of complement c1s
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
JP2005515782A (ja) 2002-01-11 2005-06-02 ジーティーシー バイオセラピューティックス インコーポレイテッド 再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
WO2004022096A1 (en) 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1693448A4 (en) 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
ES2403055T3 (es) * 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
CA3102252A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
JP5081807B2 (ja) 2005-03-16 2012-11-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 補体−媒介疾患及び状態の処置のための新規なチオフェンスルホキシイミン
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
US7999032B2 (en) 2005-07-05 2011-08-16 Kaneka Corporation Methacrylic resin composition
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
SI1991275T1 (sl) 2006-03-08 2015-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
DK1989231T3 (en) 2006-03-21 2015-08-24 Genentech Inc COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
CN101506369B (zh) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
SI2061810T1 (sl) 2006-09-05 2015-04-30 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij
CA2666466C (en) 2006-10-10 2017-11-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
US8378138B2 (en) 2006-12-19 2013-02-19 The University of Hong Kong & Versitech Limited Synthetic ion channels
WO2008097525A2 (en) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
SI2474557T1 (sl) 2007-07-16 2014-12-31 Genentech, Inc. Protiteles proti CD79b in imunokonjugati in postopki za uporabo
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
WO2009020640A2 (en) * 2007-08-08 2009-02-12 Swarmcast, Inc. Media player plug-in installation techniques
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
NZ600622A (en) 2008-08-05 2013-12-20 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US20110311550A1 (en) 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US10338080B2 (en) 2008-12-01 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
SG10201610247QA (en) * 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
SG183541A1 (en) 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
CA2833908C (en) 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
KR20130135028A (ko) 2010-05-17 2013-12-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 동물로부터 단일클론 항체의 고속 분리
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
KR101993921B1 (ko) 2010-12-06 2019-06-28 시애틀 지네틱스, 인크. Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HRP20200887T1 (hr) 2011-05-04 2020-09-04 Omeros Corporation Smjese za inhibiciju masp-2 ovisne aktivacije komplementa
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
KR101638931B1 (ko) * 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2014186599A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
HUE049769T2 (hu) * 2013-05-23 2020-10-28 Broteio Pharma B V Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik
MX375500B (es) 2013-07-09 2025-03-06 Annexon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
AU2016246452B2 (en) * 2015-04-06 2022-03-10 Bioverativ Usa Inc. Humanized anti-C1s antibodies and methods of use thereof
CN108348600A (zh) 2015-06-26 2018-07-31 比奥贝拉蒂美国公司 治疗自身免疫病症和同种免疫病症的方法
LT3525583T (lt) 2016-10-12 2025-11-10 Anti-c1s antikūnai ir jų naudojimo būdai
AU2018236267B2 (en) 2017-03-14 2025-03-13 Recordati UK Limited Methods for treating complement-mediated diseases and disorders
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
PE20201447A1 (es) 2018-04-13 2020-12-10 Chugai Pharmaceutical Co Ltd Anticuerpos anti-componente de complemento y metodos de uso
SG11202103907PA (en) 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
CN116724236A (zh) 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
CN119730882A (zh) 2022-06-24 2025-03-28 美国比奥维拉迪维股份有限公司 用于治疗补体介导的疾病的方法

Also Published As

Publication number Publication date
IL265957B1 (en) 2023-12-01
EP3525583B8 (en) 2025-09-10
CN116554320A (zh) 2023-08-08
EP3525583A4 (en) 2020-06-10
IL265957A (en) 2019-05-30
TW202434298A (zh) 2024-09-01
KR20240025715A (ko) 2024-02-27
BR112019007309A2 (pt) 2019-07-02
CA3040253A1 (en) 2018-04-19
US12391750B2 (en) 2025-08-19
ZA201902247B (en) 2024-07-31
AU2017341766A1 (en) 2019-05-23
IL308156A (en) 2023-12-01
ECSP19033211A (es) 2019-07-31
CN110300520B (zh) 2022-10-04
US20240076363A1 (en) 2024-03-07
KR102638884B1 (ko) 2024-02-22
US20200048332A1 (en) 2020-02-13
WO2018071676A1 (en) 2018-04-19
MX2024008202A (es) 2024-07-15
JP7420864B2 (ja) 2024-01-23
CN110300520A (zh) 2019-10-01
TW201821437A (zh) 2018-06-16
AU2025267421A1 (en) 2025-12-04
AU2022205174A1 (en) 2022-09-29
EP4652926A2 (en) 2025-11-26
TWI773695B (zh) 2022-08-11
CO2019004741A2 (es) 2019-07-31
DOP2019000085A (es) 2019-07-31
TN2019000109A1 (en) 2020-10-05
JP2024038319A (ja) 2024-03-19
HRP20251304T1 (hr) 2025-12-05
JP2022105114A (ja) 2022-07-12
PH12019500789A1 (en) 2019-07-29
TWI846007B (zh) 2024-06-21
AR110677A1 (es) 2019-04-24
PE20191031A1 (es) 2019-08-05
MX2019004259A (es) 2019-09-27
EP3525583B1 (en) 2025-07-23
MY198182A (en) 2023-08-09
EP3525583A1 (en) 2019-08-21
LT3525583T (lt) 2025-11-10
JP2020502996A (ja) 2020-01-30
CR20190223A (es) 2019-08-21
AU2022205174B2 (en) 2025-08-14
JP7069138B2 (ja) 2022-05-17
EA201990884A1 (ru) 2019-10-31
DK3525583T3 (da) 2025-10-27
SG11201903012RA (en) 2019-05-30
TW202246327A (zh) 2022-12-01
PT3525583T (pt) 2025-10-22
CL2019000975A1 (es) 2019-10-04
IL265957B2 (en) 2024-04-01
NZ753111A (en) 2025-06-27
KR20190082783A (ko) 2019-07-10

Similar Documents

Publication Publication Date Title
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
JP2020502996A5 (fi)
JP2019054802A5 (fi)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2016536322A5 (fi)
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
JP2018121657A5 (fi)
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
JP2018532766A5 (fi)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2019532619A5 (fi)
JP2019524693A5 (fi)
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
JP2018501197A5 (fi)
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
JP2019506841A5 (fi)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
JP2017530722A5 (fi)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2018532383A5 (fi)
RU2017105915A (ru) Антитела против pd-1
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование